Dr Woyach speaks with ecancertv at ASH 2016 about outcomes from RESONATE 1 2, finding ibrutinib suitable for patients of all ages, and how to treat when ibrutinib fails.

She discusses age-related toxicity and discontinuation of ibrutinib, especially in older and treatment naive patients, and introduces a CD19 antibody called MOR208 for patients with ibrutinib resistance mutations.

Dr Woyach considers the mutational drivers behind resistance, detectable in blood samples ahead of relapse, and how this might be a stage for pre-emptive intervention.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.